These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 30132364)
21. The Revised National Tuberculosis Control Programme in India: time for revision of treatment regimens and rapid upscaling of DOTS-plus initiative. Bhargava A; Jain Y Natl Med J India; 2008; 21(4):187-91. PubMed ID: 19267041 [No Abstract] [Full Text] [Related]
22. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan. Chien JY; Lai CC; Tan CK; Chien ST; Yu CJ; Hsueh PR J Antimicrob Chemother; 2013 Aug; 68(8):1910-6. PubMed ID: 23580558 [TBL] [Abstract][Full Text] [Related]
23. Treatment of Latent Tuberculosis Infection. Haley CA Microbiol Spectr; 2017 Apr; 5(2):. PubMed ID: 28409555 [TBL] [Abstract][Full Text] [Related]
24. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686 [TBL] [Abstract][Full Text] [Related]
25. Extensively drug-resistant tuberculosis in the United States, 1993-2007. Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626 [TBL] [Abstract][Full Text] [Related]
26. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215 [TBL] [Abstract][Full Text] [Related]
27. Treatment and prevention of tuberculosis in HIV-infected persons. Cohn DL Infect Dis Clin North Am; 1994 Jun; 8(2):399-412. PubMed ID: 8089467 [TBL] [Abstract][Full Text] [Related]
28. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [TBL] [Abstract][Full Text] [Related]
29. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087 [TBL] [Abstract][Full Text] [Related]
30. Newer Drugs for Tuberculosis Prevention and Treatment in Children. Marais BJ Indian J Pediatr; 2019 Aug; 86(8):725-731. PubMed ID: 30707347 [TBL] [Abstract][Full Text] [Related]
31. [Fight against tuberculosis in the world]. El Kamel A; Joobeur S; Skhiri N; Cheikh Mhamed S; Mribah H; Rouatbi N Rev Pneumol Clin; 2015; 71(2-3):181-7. PubMed ID: 24878188 [TBL] [Abstract][Full Text] [Related]
32. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Gray DM; Zar H; Cotton M Cochrane Database Syst Rev; 2009 Jan; (1):CD006418. PubMed ID: 19160285 [TBL] [Abstract][Full Text] [Related]
33. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Bass JB; Farer LS; Hopewell PC; O'Brien R; Jacobs RF; Ruben F; Snider DE; Thornton G Am J Respir Crit Care Med; 1994 May; 149(5):1359-74. PubMed ID: 8173779 [TBL] [Abstract][Full Text] [Related]
34. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Pablos-Mendez A; Gowda DK; Frieden TR Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008 [TBL] [Abstract][Full Text] [Related]
35. [Multidrug resistant tuberculosis in Romania in the last years (2004-2007)--an extremely important social phenomenon]. Marica C; Didilescu C; Chiotan D; Galie N; Tănăsescu M; Popescu-Hagen M; Popa M Pneumologia; 2008; 57(4):195-200. PubMed ID: 19186681 [TBL] [Abstract][Full Text] [Related]
36. Optimizing the clinical pharmacology of tuberculosis medications. Egelund EF; Alsultan A; Peloquin CA Clin Pharmacol Ther; 2015 Oct; 98(4):387-93. PubMed ID: 26138226 [TBL] [Abstract][Full Text] [Related]
38. New approaches to the treatment of latent tuberculosis. Sterling TR Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686 [TBL] [Abstract][Full Text] [Related]
39. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients. Pawar UM; Kundnani V; Agashe V; Nene A; Nene A Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244 [TBL] [Abstract][Full Text] [Related]
40. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. Yew WW Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]